• One of the main risks associated with Pradaxa or Xarelto is the lack of an antidote that can rapidly reverse their anticoagulant effects. This can make major bleeding episodes extraordinarily dangerous for people taking Pradaxa or Xarelto. In October of 2015, the FDA approved Praxbind as the first reversal agent for Pradaxa, but no such antidote for Xarelto exists. As such, there have been thousands of serious events relating to Pradaxa and Xarelto in the past two years alone. In 2014, 3,592 serious events involving Pradaxa were reported, including 752 patient deaths. An additional, 3,331 reports associated with Xarelto bleeding problems were reported as well, with 379 involving patient deaths. You can also visit for more information.

Copyright 2023, Wired Ivy, LLC

Answerbag | Terms of Service | Privacy Policy